In this early phase study, LY3437943 showed an acceptable safety profile, and its pharmacokinetics suggest suitability for once-weekly dosing. This finding, together with the pharmacodynamic findings of robust reductions in glucose and bodyweight, provides support for phase 2 development (The Lancet)
Diabetes News
Tag: GIP
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health (Journal of Clinical Endocrinology & Metabolism)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
The dual GIP and GLP-1 receptor agonist, LY3298176, showed significantly better efficacy with regard to glucose control and weight loss than did dulaglutide, with an acceptable safety and tolerability profile. Combined GIP and GLP-1 receptor stimulation might offer a new therapeutic option in the treatment of type 2 diabetes (The Lancet)
Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion
Although the success of GLP-1 analogs/mimetics in the treatment of type 2 diabetes and the correlation of strongly elevated postprandial GLP-1 levels after Roux-Y gastric bypass surgery strongly suggests benefits of recruiting endogenous GLP-1 reserves as a not yet exploited treatment alternative, the situation for GIP is less clear (Journal of Diabetes Investigation)
Glycosmedia is also available as an App: